Ethical issues and risk/benefit assessment of iron chelation therapy: Advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox

Intramuscular desferrioxamine in patients with Alzheimer's disease

MCLACHLAN, D. (1991) · The Lancet · doi:10.1016/0140-6736(91)92978-b · Cited by 764 · see citing works

Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register

Modell, B., Khan, M., & Darlison, M. W. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02357-6 · Cited by 587 · see citing works

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis

Pennell, D. J. (2005) · Blood · doi:10.1182/blood-2005-07-2948 · Cited by 490 · see citing works

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia

Anderson, L. J., Wonke, B., Prescott, E., Holden, S., Walker, J. M., & Pennell, D. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09740-4 · Cited by 431 · see citing works

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

Nisbet‐Brown, E., Olivieri, N. F., Giardina, P. J., Grady, R. W., Neufeld, E. J., Séchaud, R., Krebs‐Brown, A., Anderson, J. R., Alberti, D., Sizer, K. C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13309-0 · Cited by 326 · see citing works

A randomised comparison of deferasiroxversusdeferoxamine for the treatment of transfusional iron overload in sickle cell disease

Vichinsky, E. P., Onyekwere, O. C., Porter, J. B., Swerdlow, P. S., Eckman, J. R., Lane, P., Files, B. A., Hassell, K. L., Kelly, P. F., Wilson, F. L., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06455.x · Cited by 267 · see citing works

Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004.

Telfer, P. T., Coen, P. G., Christou, S., Hadjigavriel, M., Kolnakou, A., Pangalou, E., Pavlides, N., Psiloines, M., Simamonian, K., Skordos, G., et al. (2006) · PubMed · Cited by 190 · see citing works

Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia.

Galanello, R., Piga, A. G., Alberti, D., Rouan, M. C., Bigler, H., & Séchaud, R. (2003) · PubMed · Cited by 169 · see citing works

Development of Tridentate Iron Chelators: From Desferrithiocin to ICL670

Nick, H., Acklin, P., Lattmann, R., Buehlmayer, P., Hauffe, S., Schupp, J., & Alberti, D. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033457610 · Cited by 167 · see citing works

Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron-Chelating Agent in Patients with Transfusion-Dependent Iron Overload Due to β-Thalassemia

Galanello, R., Piga, A. G., Alberti, D., Rouan, M. C., Bigler, H., & Séchaud, R. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003253350 · Cited by 140 · see citing works

Advances in Iron Overload Therapies. Prospects for Effective Use of Deferiprone (L1), Deferoxamine, the New Experimental Chelators ICL670, GT56-252, L1NAll and their Combinations

Kontoghiorghes, G. J., Eracleous, E., Economides, C. P., & Kolnagou, A. (2005) · Current Medicinal Chemistry · doi:10.2174/092986705774463003 · Cited by 125 · see citing works

Benefits and Risks of Deferiprone in Iron Overload in Thalassaemia and Other Conditions

Kontoghiorghes, G. J., Neocleous, K., & Kolnagou, A. (2003) · Drug Safety · doi:10.2165/00002018-200326080-00003 · Cited by 112 · see citing works

The Design and Development of Deferiprone (L1) and Other Iron Chelators for Clinical Use: Targeting Methods and Application Prospects

Kontoghiorghes, G. J., Pattichis, K., Neocleous, K., & Kolnagou, A. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043364685 · Cited by 112 · see citing works

Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-ones

Kontoghiorghes, G. J., & Sheppard, L. N. (1987) · Inorganica Chimica Acta · doi:10.1016/s0020-1693(00)85549-8 · Cited by 104 · see citing works

Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil

Wood, J. C., Otto‐Duessel, M., Gonzalez, I., Aguilar, M. I., Shimada, H., Nick, H., Nelson, M. D., & Moats, R. A. (2006) · Translational research · doi:10.1016/j.trsl.2006.05.005 · Cited by 81 · see citing works

Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients

Delea, T. E., Sofrygin, O., Thomas, S. K., Baladi, J., Phatak, P. D., & Coates, T. D. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725040-00005 · Cited by 79 · see citing works

Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities

Kontoghiorghes, G. J. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.3.235 · Cited by 68 · see citing works

Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia

Henter, J., & Karlén, J. (2007) · Blood · doi:10.1182/blood-2007-02-065805 · Cited by 65 · see citing works

Safety monitoring of cardiac and hepatic systems in β‐thalassemia patients with chelating treatment in Taiwan*

Peng, C., Chow, K., Chen, J., Chiang, Y., Lin, T., & Tsai, C. (2003) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2003.00071.x · Cited by 58 · see citing works

8-Hydroxyquinoline: Chronic toxicity and inhibitory effect on the carcinogenicity of N-2-fluorenylacetamide

YAMAMOTO, R. S., Williams, G. M., Frankel, H. H., & Weisburger, J. H. (1971) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(71)90300-0 · Cited by 55 · see citing works

Effective Combination Therapy of Deferiprone and deferoxamine for the Rapid Clearance of Excess Cardiac IRON and the Prevention of Heart Disease in Thalassemia. The Protocol of the International Committee on Oral Chelators

Kolnagou, A., & Kontoghiorghes, G. J. (2006) · Hemoglobin · doi:10.1080/03630260600642567 · Cited by 46 · see citing works

Reversal of heart failure in thalassemia major by combined chelation therapy: a case report

Tsironi, M., Deftereos, S., Andriopoulos, P., Farmakis, D. T., Meletis, J., & Aessopos, A. (2004) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00335.x · Cited by 45 · see citing works

Chelators affecting iron absorption in mice.

Kontoghiorghes, G. J. (1990) · PubMed · Cited by 41 · see citing works

Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia

Kolnagou, A., Fessas, C., Papatryphonas, A., Economides, C. P., & Kontoghiorghes, G. J. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05195.x · Cited by 33 · see citing works

Future Chelation Monotherapy and Combination Therapy Strategies in Thalassemia and Other Conditions. Comparison of Deferiprone, Deferoxamine, ICL670, GT56-252, L1NAll and Starch Deferoxamine Polymers

Kontoghiorghes, G. J. (2006) · Hemoglobin · doi:10.1080/03630260600642674 · Cited by 33 · see citing works

Deferasirox: An effective once-daily orally active iron chelator

Porter, J. B. (2006) · Drugs of today · doi:10.1358/dot.2006.42.10.1009901 · Cited by 29 · see citing works

Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.

Shashaty, G. G., Frankewich, R., Chakraborti, T., Choudary, J. B., Al‐Fayoumi, S., Kacuba, A., Castillo, S., Robie‐Suh, K., Rieves, D., Weiss, K., et al. (2006) · PubMed · Cited by 24 · see citing works

Do we need more iron-chelating drugs?

Kontoghiorghes, G. J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14085-8 · Cited by 23 · see citing works

New iron-chelating drugs for the treatment of transfusional iron overload and other diseases

Kotonghiorghes, G. J. (2005) · Drugs of the Future · doi:10.1358/dof.2005.030.12.942323 · Cited by 10 · see citing works

Correlation between Dose-Dependent Reductions in Serum Transaminase (ALT) and Serum Ferritin Levels during Long-Term Chelation Therapy with Deferasirox (Exjade®, ICL670).

Brissot, P., Deugnier, Y., Cianciulli, P., Cario, H., Jeng, M., & Rabault, B. (2006) · Blood · doi:10.1182/blood.v108.11.3817.3817 · Cited by 5 · see citing works

Iron Metabolism in Cancer

Wang, Y., Lei, Y., Ding, J. P., & Chen, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010095 · Cited by 297 · see citing works

Iron as a central player and promising target in cancer progression

Jung, M., Mertens, C., Tomat, E., & Brüne, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020273 · Cited by 268 · see citing works

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes

Kontoghiorghes, G. J., & Kontoghiorghe, C. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s79458 · Cited by 176 · see citing works

Ferroptosis: mechanisms and therapeutic targets

Zhou, Q., Meng, Y., Le, J., Sun, Y., Dian, Y., Yao, L., Xiong, Y., Zeng, F., Chen, X., & Deng, G. (2024) · MedComm · doi:10.1002/mco2.70010 · Cited by 83 · see citing works

Fanconi Syndrome Due to Deferasirox

Rafat, C., Fakhouri, F., Ribeil, J., Delarue, R., & Quintrec, M. L. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.03.013 · Cited by 74 · see citing works

Acquired Proximal Renal Tubular Dysfunction in β-Thalassemia Patients Treated With Deferasirox

Yacobovich, J., Stark, P., Barzilai‐Birenbaum, S., Krause, I., Pazgal, I., Yaniv, I., & Tamary, H. (2010) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e3181ec0c38 · Cited by 58 · see citing works

World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients

Kontoghiorghe, C. (2014) · World Journal of Methodology · doi:10.5662/wjm.v4.i3.163 · Cited by 59 · see citing works

New developments and controversies in iron metabolism and iron chelation therapy

Kontoghiorghe, C., & Kontoghiorghes, G. J. (2016) · World Journal of Methodology · doi:10.5662/wjm.v6.i1.1 · Cited by 52 · see citing works

Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy

Kolnagou, A., Kleanthous, M., & Kontoghiorghes, G. J. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01499.x · Cited by 51 · see citing works

The footprints of mitochondrial impairment and cellular energy crisis in the pathogenesis of xenobiotics-induced nephrotoxicity, serum electrolytes imbalance, and Fanconi’s syndrome: A comprehensive review

Heidari, R. (2019) · Toxicology · doi:10.1016/j.tox.2019.05.002 · Cited by 50 · see citing works

A New Era in Iron Chelation Therapy: The Design of Optimal, Individually Adjusted Iron Chelation Therapies for the Complete Removal of Iron Overload in Thalassemia and other Chronically Transfused Patients

Kontoghiorghes, G. J. (2009) · Hemoglobin · doi:10.3109/03630260903217182 · Cited by 40 · see citing works

Anti‑CD206 antibody‑conjugated Fe3O4‑based PLGA nanoparticles selectively promote tumor‑associated macrophages to polarize to the pro‑inflammatory subtype

Zhou, Y., Que, K., Tang, H., Zhang, P., Fu, Q., & Liu, Z. (2020) · Oncology Letters · doi:10.3892/ol.2020.12161 · Cited by 38 · see citing works

Fanconi syndrome in a patient with β‐thalassemia major after using deferasirox for 27 months

Wei, H., Yang, C., Cheng, C., & Lo, F. (2010) · Transfusion · doi:10.1111/j.1537-2995.2010.02939.x · Cited by 34 · see citing works

Ocular abnormalities in multi-transfused beta-thalassemia patients

Heydarian, S., Jafari, R., Karami, H., Shektaei, M., Dailami, K. N., Amiri, A. A., Rezaee, M. R. S., & Far, A. F. (2015) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.170986 · Cited by 34 · see citing works

Myelodysplasia paranoia: Iron as the new radon

Steensma, D. P. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.10.017 · Cited by 34 · see citing works

Advances in the Prevention and Treatment are Changing Thalassemia from a Fatal to a Chronic Disease. Experience from a Cyprus Model and its Use as a Paradigm for Future Applications

Kolnagou, A., & Kontoghiorghes, G. J. (2009) · Hemoglobin · doi:10.3109/03630260903212043 · Cited by 31 · see citing works

Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases

Kolnagou, A. (2014) · World Journal of Methodology · doi:10.5662/wjm.v4.i4.197 · Cited by 29 · see citing works

Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities

Kontoghiorghes, G. J. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2010.497138 · Cited by 29 · see citing works

Effectiveness of deferiprone in transfusion‐independent beta‐thalassemia/HbE patients

Akrawinthawong, K., Chaowalit, N., Chatuparisuth, T., & Siritanaratkul, N. (2011) · Hematology · doi:10.1179/102453311x12940641877768 · Cited by 26 · see citing works

Iron-chelation therapy with oral chelators in patients with thalassemia major

Uygun, V., & Kurtoğlu, E. (2013) · Hematology · doi:10.1179/1607845412y.0000000046 · Cited by 22 · see citing works

The emerging role and therapeutical implications of ferroptosis in wound healing

Zhao, Y., Chen, Z., Xie, S., Xiao, F., Hu, Q., & Ju, Z. (2024) · Burns & Trauma · doi:10.1093/burnst/tkae082 · Cited by 21 · see citing works

A bis(3-hydroxy-4-pyridinone)-EDTA derivative as a strong chelator for M3+ hard metal ions: complexation ability and selectivity

Gama, S., Dron, P. I., Chaves, S., Farkas, E., & Santos, M. A. (2009) · Dalton Transactions · doi:10.1039/b904950a · Cited by 21 · see citing works

Synthesis and biological properties of iron chelators based on a bis-2-(2-hydroxy-phenyl)-thiazole-4-carboxamide or -thiocarboxamide (BHPTC) scaffold

Rodríguez‐Lucena, D., Gaboriau, F., Rivault, F., Schalk, I. J., Lescoat, G., & Mislin, G. L. A. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.11.057 · Cited by 18 · see citing works

Deferasirox induced liver injury in haemochromatosis.

Aslam, N., Mettu, P., Marsano, L. S., & Martin, A. (2010) · PubMed · Cited by 17 · see citing works

Transparency and Access to Full Information for the Fatal or Serious Toxicity Risks, Low Efficacy and High Price of Deferasirox, Could Increase the Prospect of Improved Iron Chelation Therapy Worldwide

Kontoghiorghes, G. J. (2008) · Hemoglobin · doi:10.1080/03630260802341703 · Cited by 17 · see citing works

The Relevance of Iron Overload and the Appropriateness of Iron Chelation Therapy for Patients with Myelodysplastic Syndromes: A Dialogue and Debate

Steensma, D. P. (2011) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-011-0084-z · Cited by 16 · see citing works

Ethical Issues and Risk/Benefit Assessment of Iron Chelation Therapy: Advances with Deferiprone/deferoxamine Combinations and Concerns about the Safety, Efficacy and Costs of Deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1–2):1–15.]

Porter, J. B., Taher, A. T., Cappellini, M. D., & Vichinsky, E. P. (2008) · Hemoglobin · doi:10.1080/03630260802342008 · Cited by 16 · see citing works

Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues

Ioannidis, I., Lefkaritis, G., Georgiades, S. N., Pashalidis, I., & Kontoghiorghes, G. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115954 · Cited by 15 · see citing works

PHARMACOLOGICAL PROPERTIES OF ORALLY AVAILABLE, AMPHIPATHIC POLYAMINOCARBOXYLIC ACID CHELATORS FOR ACTINIDE DECORPORATION

Miller, S. C., Wang, X., & Bowman, B. M. (2010) · Health Physics · doi:10.1097/hp.0b013e3181bfb99b · Cited by 14 · see citing works

TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo

Kalanaky, S., Hafizi, M., Safari, S., Mousavizadeh‬, K., Kabiri, M., Farsinejad, A., Fakharzadeh, S., & Nazaran, M. H. (2016) · International Journal of Hematology · doi:10.1007/s12185-015-1932-8 · Cited by 12 · see citing works

Pattern and clinical profile of thalassemia among pediatric patients attending the Yemeni Society Centers for Thalassemia and Genetic Blood Disorders in Yemen

Al-Kherbash, H. A., Al-Awdi, A., & Hasan, N. S. (2017) · The Scientific Journal of Al-Azhar Medical Faculty Girls · doi:10.4103/sjamf.sjamf_15_17 · Cited by 12 · see citing works

Refractive errors and ocular biometry components in thalassemia major patients

Heydarian, S., Jafari, R., & Karami, H. (2015) · International Ophthalmology · doi:10.1007/s10792-015-0161-8 · Cited by 10 · see citing works

DIBI, a novel 3-hydroxypyridin-4-one chelator iron-binding polymer, inhibits breast cancer cell growth and functions as a chemosensitizer by promoting S-phase DNA damage

Greenshields, A. L., Coombs, M. R. P., Fernando, W., Holbein, B. E., & Hoskin, D. W. (2019) · BioMetals · doi:10.1007/s10534-019-00222-3 · Cited by 9 · see citing works

Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients

Kontoghiorghes, G. J. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740330802137479 · Cited by 9 · see citing works

A Record Of 1320 Suspect, Deferasirox-Related, Patient Deaths Reported In 2009: Insufficient Toxicity Testing, Low Efficacy And Lack Of Transparency May Endanger The Lives Of Iron Loaded Patients

Kontoghiorghes, G. J. (2011) · Hemoglobin · doi:10.3109/03630269.2011.576906 · Cited by 9 · see citing works

Puzzling out iron complications in cancer drug resistance

Abedi, M., & Rahgozar, S. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103772 · Cited by 8 · see citing works

Is Deferasirox Implicated in Multiple Organ Failure in a Patient With Homozygous β-Thalassemia?

Vlachaki, E., Chatzinikolaou, K., Bekiari, E., Klonizakis, P., & Τσάπας, Α. (2011) · Angiology · doi:10.1177/0003319710394160 · Cited by 6 · see citing works

Síndrome de hipersensibilidad retardada inducido por deferasirox

Macías, A. G., Palacios, E. L., Olabarría, I., & Odriozola, P. M. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2008.12.004 · Cited by 5 · see citing works

Experience with Combination Therapy of Deferiprone and Desferrioxamine in β-Thalassemia Major Patients with Iron Overload at Maternity and Children Hospital, Al Madinah Al Munawarah, Saudi Arabia

Hawsawi, Z. M. A., Sairafy, M. H., Tarawah, A., Zolaly, M. A., & Hegaily, A. R. S. A. (2010) · Journal of Taibah University Medical Sciences · doi:10.1016/s1658-3612(10)70121-9 · Cited by 4 · see citing works

Questioning Established Theories and Treatment Methods Related to Iron and Other Metal Metabolic Changes, Affecting All Major Diseases and Billions of Patients

Kontoghiorghes, G. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031364 · Cited by 4 · see citing works

Physico-Chemical Properties of bis -2-(2-Hydroxyphenyl)-thiazole-carboxamide (BHPTC) Chelators

Hmadeh, M., Mazan, V., Rodríguez‐Lucena, D., Hoegy, F., Platas‐Iglesias, C., Mislin, G. L. A., & Elhabiri, M. (2026) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.5c05413 · Cited by 1 · see citing works

23 Metal antagonists

Meyboom, R. H. B. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29023-8

Impact of new chelating agents on ocular abnormalities in β-thalassemia major patients

Abo-Zied, S., Elgemaey, H. M., & Abd-Aal, H. (2021) · Alexandria Journal of Pediatrics · doi:10.4103/ajop.ajop_33_21

Toxic Ingestions

Sullivan, J. E., & McDonald, M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6362-6_50

Deferasirox

(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00063-9

Metal antagonists

Meyboom, R. H. B. (2010) · Side effects of drugs annual · doi:10.1016/s0378-6080(10)32023-x

Iron Chelator Drugs in Transfusion Dependent Thalassemia: a Review

Hashemieh, M. (2020) · Armaghane Danesh · doi:10.52547/armaghanj.25.4.529

Epidemiological features and clinical profile of patients with thalassemia in Kabul, Afganisthan

Saeed, K. M. I. (2024) · Journal of Hematology and Allied Sciences · doi:10.25259/jhas_28_2024

Application of Fuzzy AHP for Medication Decision Making in Iron-Chelating Medications for Thalassemia

Barzegari, S., Rostamian, H., Firoozi-Majd, E., & Arpacı, İ. (2025) · Pharmacy · doi:10.3390/pharmacy13030086

New iron-chelating drugs for the treatment of transfusional iron overload and other diseases

Kotonghiorghes, G. J. (2005) · Drugs of the Future · doi:10.1358/dof.2005.030.12.942323 · Cited by 10 · see citing works

The Proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies

Kontoghiorghes, G. J. (2012) · Toxicology Mechanisms and Methods · doi:10.3109/15376516.2012.720305 · Cited by 11 · see citing works

New chelation therapies and emerging chelating drugs for the treatment of iron overload

Kontoghiorghes, G. J. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.1.1 · Cited by 20 · see citing works

The Proceedings Of The 19Th International Conference On Chelation Held In London, United Kingdom: Major Changes In Iron Chelation Therapy In The Last 25 Years Using Deferiprone (L1) Has Resulted In The Complete Treatment Of Iron Overload

Kontoghiorghes, G. J. (2011) · Hemoglobin · doi:10.3109/03630269.2011.575663

Iron Chelation Therapy for Transfusional Iron Overload: A Swift Evolution

Musallam, K. M., & Taher, A. T. (2011) · Hemoglobin · doi:10.3109/03630269.2011.608228 · Cited by 10 · see citing works